RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026
RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026
RenovoRx (NASDAQ:RNXT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026 [Yahoo! Finance]
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026